IMATINIB MESILATE

eu gmp and active usdmf available

TWO QUALITIES AVAILABLE

IMATINIB MESILATE (CAS 220127-57-1) is a tyrosine-kinase inhibitor, which is used in the treatment of multiple cancers, most notably Philadelphia chromo-some-positive (Ph+) chronic myelogenous leukemia (CML). It is on WHO’s “List of Essential Drugs."

MARKET INFORMATION

Originator: NOVARTIS
Originator product: GLEEVEC®/GLIVEC®
Core patent exclusivity expired in December 2015

YOUR ADVANTAGES   

  • FDA-approved, WC available
  • EU-GMP available
  • Two qualities available (lower quality with higher impurities but still following the EP draft)

This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.